Park, H.A., Neumeyer, S., Michailidou, K. et al. Mendelian randomisation study of smoking exposure in relation to breast cancer risk. Br J Cancer 125, 1135–1145 (2021). https://doi.org/10.1038/s41416-021-01432-8
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
|Author:||Park, Hanla A.1,2; Neumeyer, Sonja1; Michailidou, Kyriaki3,4,5;|
1German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
2Heidelberg Univ, Fac Med, Heidelberg, Germany.
3Cyprus Inst Neurol & Genet, Biostat Unit, Nicosia, Cyprus.
4Cyprus Inst Neurol & Genet, Cyprus Sch Mol Med, Nicosia, Cyprus.
5Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England.
6NCI, Div Canc Epidemiol & Genet, NIH, US Dept HHS, Bethesda, MD 20892 USA.
7Mt Sinai Hosp, Fred A Litwin Ctr Canc Genet, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
8Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
9Univ Calif Irvine, Genet Epidemiol Res Inst, Dept Epidemiol, Irvine, CA USA.
10NN Alexandrov Res Inst Oncol & Med Radiol, Minsk, BELARUS.
11German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
12Queens Univ, Canc Res Inst, Dept Publ Hlth Sci, Kingston, ON, Canada.
13Lund Univ, Dept Canc Epidemiol, Clin Sci, Lund, Sweden.
14Univ Hosp Leuven, Leuven Multidisciplinary Breast Ctr, Leuven Canc Inst, Dept Oncol, Leuven, Belgium.
15Univ Med Ctr Hamburg Eppendorf, Inst Med Biometry & Epidemiol, Hamburg, Germany.
16Charite Univ Med Berlin, Inst Biometry & Clin Epidemiol, Berlin, Germany.
17Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr ER EMN, Dept Gynecol & Obstet, Erlangen, Germany.
18Ctr Invest Red Enfermedades Raras CIBERER, Madrid, Spain.
19Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Programme, Madrid, Spain.
20Russian Acad Sci, Inst Biochem & Genet, Ufa Fed Res Ctr, Ufa, Russia.
21Hannover Med Sch, Dept Radiat Oncol, Hannover, Germany.
22Hannover Med Sch, Gynaecol Res Unit, Hannover, Germany.
23Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Copenhagen Gen Populat Study, Herlev, Denmark.
24Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Clin Biochem, Herlev, Denmark.
25Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
26Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
27Univ Tubingen, iFIT Cluster Excellence, Tubingen, Germany.
28German Canc Res Ctr, German Canc Consortium DKTK, Partner Site Tubingen, Tubingen, Germany.
29German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.
30Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
31German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.
32Univ Tubingen, Dept Gynecol & Obstet, Tubingen, Germany.
33German Canc Res Ctr, Mol Epidemiol Grp, C080, Heidelberg, Germany.
34Heidelberg Univ, Univ Womens Clin Heidelberg, Mol Biol Breast Canc, Heidelberg, Germany.
35Univ Pisa, Dept Biol, Pisa, Italy.
36German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany.
37Xerencia Xest Integrada Vigo SERGAS, Oncol & Genet Unit, Inst Invest Sanitaria Galicia Sur IISGS, Vigo, Spain.
38QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Brisbane, Qld, Australia.
39Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
40Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge, England.
41Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
42Univ Sheffield, Sheffield Inst Nucl Acids SInFoNiA, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
43Univ Sheffield, Acad Unit Pathol, Dept Neurosci, Sheffield, S Yorkshire, England.
44Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
45Fox Chase Canc Ctr, Dept Clin Genet, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
46Leiden Univ Med Ctr, Dept Pathol, Leiden, Netherlands.
47Leiden Univ Med Ctr, Dept Human Genet, Leiden, Netherlands.
48London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England.
49Univ Westminster, Sch Life Sci, London, England.
50Univ Southampton, Fac Med, Southampton, Hants, England.
51Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
52Harvard Med Sch, Boston, MA 02115 USA.
53Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
54Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany.
55Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Biol Sci,Div Evolut & Genom Sci, Manchester, Lancs, England.
56Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, North West Genom Lab Hub,St Marys Hosp, Manchester, Lancs, England.
57Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
58Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Breast Surg, Herlev, Denmark.
59Curtin Univ, Sch Publ Hlth, Perth, WA, Australia.
60Ctr Invest Biomed Red Canc CIBERONC, Inst Invest Sanitaria San Carlos IdISSC, Hosp Clin San Carlos, Med Oncol Dept, Madrid, Spain.
61Amer Canc Soc, Behav & Epidemiol Res Grp, Atlanta, GA 30329 USA.
62Canc Council Victoria, Canc Epidemiol Div, Melbourne, Vic, Australia.
63Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
64Monash Univ, Sch Clin Sci, Precis Med, Monash Hlth, Clayton, Vic, Australia.
65McGill Univ, Dept Med, Montreal, PQ, Canada.
66McGill Univ, Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ, Canada.
67Univ Utah, Huntsman Canc Inst, Dept Dermatol, Sch Med, Salt Lake City, UT USA.
68Univ Oulu, Oulu Univ Hosp, Dept Surg, Oulu, Finland.
69Univ Paris Sud, Univ Paris Saclay, Ctr Res Epidemiol & Populat Hlth CESP, INSERM,Canc & Environm Grp, Villejuif, France.
70Univ Cologne, Fac Med, Ctr Familial Breast & Ovarian Canc, Cologne, Germany.
71Univ Cologne, Univ Hosp Cologne, Cologne, Germany.
72Univ Cologne, Fac Med, Ctr Integrated Oncol CIO, Cologne, Germany.
73Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
74Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
75Soder Sjukhuset, Dept Oncol, Stockholm, Sweden.
76German Canc Res Ctr, Mol Genet Breast Canc, Heidelberg, Germany.
77Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Informat Imaging & Data Sci, Manchester, Lancs, England.
78Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Nightingale & Genesis Prevent Ctr, Manchester, Lancs, England.
79Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Unit, Manchester, Lancs, England.
80Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
81Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands.
82Harvard TH Chan Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Boston, MA USA.
83Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England.
84Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland.
85Pomeranian Med Univ, Independent Lab Mol Biol & Genet Diagnost, Szczecin, Poland.
86Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA 94305 USA.
87Stanford Univ, Stanford Canc Inst, Dept Med, Div Oncol,Sch Med, Stanford, CA 94305 USA.
88Antoni van Leeuwenhoek Hosp, Div Mol Pathol, Netherlands Canc Inst, Amsterdam, Netherlands.
89Bashkir State Univ, Dept Genet & Fundamental Med, Ufa, Russia.
90NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
91Erasmus MC Canc Inst, Dept Surg Oncol, Family Canc Clin, Rotterdam, Netherlands.
92Oslo Univ Hosp, Med Genet, Oslo, Norway.
93Univ Oslo, Oslo, Norway.
94City Hope Natl Med Ctr, Dept Computat & Quantitat Med, Duarte, CA USA.
95City Hope Natl Med Ctr, City Hope Comprehens Canc Ctr, Duarte, CA USA.
96VIB Ctr Canc Biol, Leuven, Belgium.
97Univ Leuven, Dept Human Genet, Lab Translat Genet, Leuven, Belgium.
98Univ Hawaii Canc Ctr, Epidemiol Program, Honolulu, HI USA.
99Univ Tubingen, Tubingen, Germany.
100Univ Eastern Finland, Translat Canc Res Area, Kuopio, Finland.
101Univ Eastern Finland, Inst Clin Med Pathol & Forens Med, Kuopio, Finland.
102Kuopio Univ Hosp, Biobank Eastern Finland, Kuopio, Finland.
103Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden.
104Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
105Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA.
106Univ Hosp Heraklion, Dept Med Oncol, Iraklion, Greece.
107Univ Munich, Dept Gynecol & Obstet, Campus Grosshadern, Munich, Germany.
108UCL, Inst Clin Trials & Methodol, MRC Clin Trials Unit UCL, London, England.
109Univ Helsinki, Helsinki Univ Hosp, Dept Obstet & Gynecol, Helsinki, Finland.
110Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, Clin Genet Res Lab, 1275 York Ave, New York, NY 10021 USA.
111Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, 1275 York Ave, New York, NY 10021 USA.
112Univ North Carolina Chapel Hill, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
113Univ North Carolina Chapel Hill, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
114IFOM FIRC Inst Mol Oncol, Genome Diagnost Program, Milan, Italy.
115MASA, Res Ctr Genet Engn & Biotechnol Georgi D Efremov, Skopje, North Macedonia.
116Fdn IRCCS Ist Nazl Tumori INT, Dept Res, Unit Mol Bases Genet Risk & Genet Testing, Milan, Italy.
117Carmel Hosp, Clalit Natl Canc Control Ctr, Haifa, Israel.
118Technion Fac Med, Haifa, Israel.
119Hosp Univ Puerta de Hierro, Med Oncol Dept, Madrid, Spain.
120Univ Hosp Larissa, Dept Oncol, Larisa, Greece.
121Kings Coll London, Comprehens Canc Ctr, Sch Canc & Pharmaceut Sci, Guys Campus, London, England.
122Antoni van Leeuwenhoek Hosp, Div Psychosocial Res & Epidemiol, Netherlands Canc Inst, Amsterdam, Netherlands.
123Univ Cologne, Fac Med, Ctr Mol Med Cologne CMMC, Cologne, Germany.
124Inst Canc Res, Div Genet & Epidemiol, London, England.
125Univ Hosp Ulm, Dept Gynaecol & Obstet, Ulm, Germany.
126Vanderbilt Univ, Vanderbilt Epidemiol Ctr, Vanderbilt Ingram Canc Ctr, Dept Med,Sch Med, Nashville, TN USA.
127Univ Laval Res Ctr, Ctr Hosp Univ Quebec, Genom Ctr, Quebec City, PQ, Canada.
128Univ Hosp Leuven, Dept Surg Oncol, Leuven, Belgium.
129Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia.
130BC Canc, Populat Oncol, Vancouver, BC, Canada.
131Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.
132Inst Canc Res, Div Breast Canc Res, London, England.
133NIEHS, Epidemiol Branch, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
134NIEHS, Epigenet & Stem Cell Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
135Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
136Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England.
137Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
138Univ Oxford, Oxford NIHR Biomed Res Ctr, Oxford, England.
139Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN USA.
140Univ Oulu, Bioctr Oulu, Canc & Translat Med Res Unit, Lab Canc Genet & Tumor Biol, Oulu, Finland.
141Northern Finland Lab Ctr Oulu, Lab Canc Genet & Tumor Biol, Oulu, Finland.
142Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
143Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg UCCH, Canc Epidemiol Grp, Hamburg, Germany.
|Online Access:||PDF Full Text (PDF, 1 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022040527203
|Publish Date:|| 2022-04-05
Background: Despite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological studies, it is still equivocal whether smoking is causally related to breast cancer risk.
Methods: We applied Mendelian randomisation (MR) to evaluate a potential causal effect of cigarette smoking on breast cancer risk. Both individual-level data as well as summary statistics for 164 single-nucleotide polymorphisms (SNPs) reported in genome-wide association studies of lifetime smoking index (LSI) or cigarette per day (CPD) were used to obtain MR effect estimates. Data from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted among ever-smokers from 26,147 cancer cases and 26,072 controls. Sensitivity analyses were conducted to address pleiotropy.
Results: Genetically predicted LSI was associated with increased breast cancer risk (OR 1.18 per SD, 95% CI: 1.07–1.30, P = 0.11 × 10⁻²), but there was no evidence of association for genetically predicted CPD (OR 1.02, 95% CI: 0.78–1.19, P = 0.85). The sensitivity analyses yielded similar results and showed no strong evidence of pleiotropic effect.
Conclusions: Our MR study provides supportive evidence for a potential causal association with breast cancer risk for lifetime smoking exposure but not cigarettes per day among smokers.
British journal of cancer
|Pages:||1135 - 1145|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and by the European Community's Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research Innovation du Quebec through Genome Quebec and the PSR-SIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175) C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 -the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE Consortium was funded by U19 CA148065. The Australian Breast Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organisations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). The BCEES was funded by the National Health and Medical Research Council, Australia. For the BCFR-NY, BCFRPA, BCFR-UT, this work was supported by grant UM1 CA164920 from the National Cancer Institute.; The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government or the BCFR. For BIGGS, ES is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. The BREast Oncology GAlician Network (BREOGAN) is funded by Accion Estrategica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Accion Estrategica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Conselleria de Industria Programa Sectorial de Investigacion Aplicada, PEME I + D e I + D Suma del Plan Gallego de Investigacion, Desarrollo e Innovacion Tecnologica de la Conselleria de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigacion Clinica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDERInnterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center and the Canadian Institutes of Health Research. CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Securite Sanitaire, de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Tematica de Investigacion Cooperativa en Cancer and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario creation, maintenance, and updating of the CPS-II cohort. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398, UM1 CA164917 and U01 CA199277). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The University of Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer.; The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) C8221/A19170 to EPICOxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPICOxford) (United Kingdom). The ESTHER study was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR 0707-10031. The GC-HBOC (German Consortium of Hereditary Breast and Ovarian Cancer) is supported by the German Cancer Aid (grant no 110837, coordinator: Rita K. Schmutzler, Cologne). This work was also funded by the European Regional Development Fund and Free State of Saxony, Germany (LIFE-Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 14505/2470, 14575/2470). The GENICA was funded by the Federal Ministry of Education and Research the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. Generation Scotland (GENSCOT) received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Funding for identification of cases and contribution to BCAC funded in part by the Wellcome Trust Seed Award "Temporal trends in incidence and mortality of molecular subtypes of breast cancer to inform public health, policy and prevention" Reference 207800/Z/17/Z. The GEPARSIXTO study was conducted by the German Breast Group GmbH. The GESBC was supported by the Deutsche Krebshilfe e. V.  and the German Cancer Research Center (DKFZ). GLACIER was supported by Breast Cancer Now, CRUK and Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The HABCS study was supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, and by the Rudolf Bartling Foundation. The HEBCS was financially supported by the Helsinki University Hospital Research Fund, the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HMBCS was supported by a grant from the Friends of Hannover Medical School and by the Rudolf Bartling Foundation.; The HUBCS was supported by a grant from the German Federal Ministry of Research and Education (RUS08/017), M.B. was supported by grant 17-44-020498, 17-29-06014 of the Russian Foundation for Basic Research, E.K was supported by the program for support the bioresource collections.007-030164/2, and the study was performed as part of the assignment of the Ministry of Science and Higher Education of the Russian Federation (NO. AAAA-A16-116020350032-1). Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation. The KARMA study was supported by Marit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01-1-0729], Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; 400413, 400281, 199600). LMBC is supported by the 'Stichting tegen Kanker'. D.L. is supported by the FWO. The MABCS study is funded by the Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", MASA. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5x1000"). The MCBCS was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation. The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The MEC was supported by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973.; The MISS study is supported by funding from ERC-2011-294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program-grant #CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade-grant #PSR-SIIRI-701. The NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer Research; the Research Council of Norway grant 193387/V50 (to A.-L. Borresen-Dale and V.N. Kristensen) and grant 193387/H10 (to A.-L. Borresen-Dale and V.N. Kristensen), South Eastern Norway Health Authority (grant 39346 to A.-L. Borresen-Dale) and the Norwegian Cancer Society (to A.-L. Borresen-Dale and V.N. Kristensen). The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The Northern California Breast Cancer Family Registry supported by grants U01CA164920 and U01CA167551 from the USA National Cancer Institute of the National Institutes of Health. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR) or the Colon Cancer Family Registry organisations imply endorsement by the USA Government or the BCFR or CCFR. The Carolina Breast Cancer Study (NCBCS) was funded by Komen Foundation, the National Cancer Institute (P50 CA058223, U54 CA156733, U01 CA179715), and the North Carolina University Cancer Research Fund. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107 and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065. The OBCS was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland (grant number 250083, 122715 and Center of Excellence grant number 251314), the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation and the special Governmental EVO funds for Oulu University Hospital-based research activities. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. The POSH study is funded by Cancer Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast Cancer Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-10031.; The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health supported by Sheffield Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. The Two Sister Study (2SISTER) was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES102245), and, also by a grant from Susan G. Komen for the Cure, grant FAS0703856. SKKDKFZS is supported by the DKFZ. The SMC is funded by the Swedish Cancer Foundation and the Swedish Research Council (VR 2017-00644) grant for the Swedish Infrastructure for Medical Population-based Life-course Environmental Research (SIMPL+++ER). The SZBCS was supported by Grant PBZ_KBN_122/P05/2004 and the program of the Minister of Science and Higher Education under the name "Regional Initiative of Excellence" in 2019-2022 project number 002/RID/2018/19 amount of financing 12 000 000 PLN. The TNBCC was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and MRC core funding (MR_UU_12023). The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Open Access funding enabled and organized by Projekt DEAL.
|Academy of Finland Grant Number:||
250083 (Academy of Finland Funding decision)
122715 (Academy of Finland Funding decision)
251314 (Academy of Finland Funding decision)
© The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.